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ABSTRACT 11 
Ten analogues of a teicoplanin pseudoaglycon derivative have been synthesized with the 12 
aim of optimizing the in vitro activity of the compound against VanA type vancomycin resistant 13 
enterococci (VRE) isolated from hospitalized patients. Teicoplanin, vancomycin and oritavancin 14 
were used as reference antibiotics for the antibacterial evaluations. One of the new derivatives 15 
exhibited far superior activity than the original compound. The in vitro MICs measured were 16 
comparable to that of oritavancin against the investigated VRE strains. 17 
 18 
INTRODUCTION 19 
When resistance to the first beta lactam – penicillin - started to emerge, vancomycin was 20 
the first glycopeptide antibiotic used for the treatment of Gram-positive bacterial infections with 21 
clinical success. A few decades later the usage of vancomycin heavily increased, which definitely 22 
contributed to the development of vancomycin resistance by enterococci, followed by the vanA 23 
gene mediated teicoplanin resistance in the 1990s [1]. By the 21st century, antibiotic resistance has 24 
become one of the most challenging problems in public healthcare. The demand for new 25 
antibacterial drugs including glycopeptide antibiotics stimulated the development of semisynthetic 26 
derivatives which have better pharmacokinetic profiles or higher activity against resistant 27 
pathogens than those on the market. This resulted in the successful launch of oritavancin, a 28 
chloroeremomycin derivative which is known to have exceptionally high activity along with 29 
concentration dependent bactericidal effect against a wide range of glycopeptide resistant 30 
enterococci, including VanA strains [2]. 31 
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For many years our group has been working on the synthesis of new glycopeptides using 32 
different parent antibiotics as starting compounds, focusing on N-terminal modifications by a wide 33 
range of chemical reactions [3, 4]. So far, the most potent derivatives appear to be those of 34 
teicoplanin [5, 6]. Teicoplanin (Fig. 1) is a mixture of six major (A2-1-5 and A3-1, which lacks the 35 
N-acyl-glucosamine moiety) and minor components, and is used in such form, however the exact 36 
composition suitable for clinical use is more or less strictly stated in pharmacopoeias e. g. Ph. Eur. 37 
9.0. For the sake of synthetic simplicity, we have mainly synthesized lipophilic derivatives of the 38 
teicoplanin pseudoaglycon [5-7], that proved to be highly active even against multiresistant Gram-39 
positive strains. 40 
Recently we have reported on the in vitro antibacterial activity of teicoplanin 41 
pseudoaglycon derivatives bearing various N-terminal side chain moieties against a collection of 42 
vancomycin resistant enterococci [7]. One of the compounds (1, Fig. 2), a triazole derivative, 43 
showed significantly lower MIC values compared to the others, although many of the strains were 44 
not susceptible to either of the compounds.  45 
In the SAR studies of teicoplanin derivatives, highly vancomycin or teicoplanin resistant 46 
enterococci seem to have not been widely investigated. Practically, hardly any of the publications 47 
describing the classical modifications of teicoplanin (e.g. deglycosylation [8], N-alkylation [9], 48 
ester and amide formation [10, 11], a combination of these [12], N-acylation [13], synthesis of 49 
thioureas [14], etc.) mention activities against teicoplanin resistant strains, which might be due to 50 
the less common occurrence of VanA type enterococci at that time. Importantly however, after the 51 
synthesis and in vivo evaluation of several of those compounds, a general finding of the Lepetit 52 
Group was, that derivatives on which the N-acyl-D-glucosamine moiety is present are likely to have 53 
superior pharmacokinetics. 54 
In a later publication by Malabarba et al., the role of the N-acetyl-D-glucosamine moiety in 55 
the antibacterial activity was carefully investigated [15]. Using reductive reaction conditions, they 56 
have managed to selectively remove the N-acetyl-glucosamine, which is not possible by the 57 
traditional acid hydrolysis methods. In that paper, several teicoplanin resistant E. faecalis and E. 58 
faecium strains were used for the antibacterial evaluations. The main finding was, that the selective 59 
removal of the N-acetyl-glucosamine resulted in more active compounds against VRE, thus, the 60 
presence of this sugar is unfavorable for anti-VRE activity. This might still not clearly answer, 61 
whether the classical, gradual acidic deglycosylation (i.e. the removal of N-acyl--D-glucosamine, 62 
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-D-mannose, and the N-acetyl--D-glucosamine, in that order) of a certain derivative yields 63 
compounds with better or weaker in vitro activity against VRE. 64 
The transformation of the terminal carboxyl function of teicoplanin-like antibiotics into 65 
different amides with basic character is known to frequently enhance the antibacterial activity and 66 
in vivo efficacy [11]. The improvement is usually more observable against staphylococci, but the 67 
susceptibility of resistant enterococci to such amide derivatives is also likely to increase, as it was 68 
demonstrated in the case of the structurally related antibiotic A-40926 [16]. 69 
Considering the above facts, by synthesizing several analogues of compound 1, we 70 
investigated the influence of different degrees of deglycosylation, the modification of the C-71 
terminus or both on the antibacterial activity, including the potency against clinical isolates of VRE. 72 
Here, we present the synthesis and the in vitro antibacterial properties of the new derivatives. 73 
 74 
RESULTS AND DISCUSSION 75 
Synthesis 76 
For the modification of the C-terminus 3-(dimethylamino)-1-propylamine was chosen for 77 
amide formation, since this moiety seems to enhance the activity rather consistently for teicoplanin 78 
and related glycopeptides e. g. dalbavancin, the semisynthetic A-40926 derivative [11, 16]. To 79 
slightly increase the lipophilicity, 3-(diethylamino)-1-propylamine was also used for the C-80 
terminal modification (except for teicoplanin A2). 81 
The synthesis began with the preparation of compound 1 by following the procedure we 82 
have already published [6]. From this compound, the two amide analogues 2 and 3 were prepared 83 
by using 3-(dimethylamino)-1-propylamine and 3-(diethylamino)-1-propylamine, respectively and 84 
PyBOP as the peptide coupling reagent (Scheme 1). 85 
Triazole derivatives of the other type of pseudoaglycon (teicoplanin A3-1) and the aglycon 86 
(Scheme 2 and Scheme 3) were prepared as follows: deglycosylation reactions were carried out as 87 
they are described in the literature [9]. The hydrolysis products were then transformed into the 88 
corresponding azido derivatives by the method described earlier [6], and finally the Cu(I)-catalyzed 89 
azide-alkyne cycloaddition (CuAAC) gave triazole derivatives 4 and 7 of teicoplanin A3-1 and 90 
teicoplanin aglycon, respectively. 91 
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Amides 5 and 6 were prepared from derivative 4 by the same method as described for 2 and 92 
3 above. The peptide coupling reaction of the aglycon derivative 7 with the selected amines 93 
successfully yielded amides 8 and 9 (Scheme 4). 94 
Finally, the azido derivative from the teicoplanin mixture was prepared by diazotransfer, 95 
followed by CuAAC to give the triazole derivative 10 (Scheme 5a). After normal phase flash 96 
chromatography and Sephadex LH-20 gel chromatography we analyzed the composition of our 97 
newly obtained teicoplanin mixture by RP-HPLC-ESI-MS (see chromatogram and analysis in 98 
supporting information, page S29).  The main components (~80%) were found to be the expected 99 
triazole derivatives of the A2-2 and A2-3 factors in cca. 2:1 ratio. Smaller amounts of the A2-1, A2-100 
4 and A2-5 factors (cca. 8-10%) and the A3-1 analogue (~5%) (same as compound 4) were also 101 
detected along with small amounts of unidentifiable products. 102 
The amide analogue 11 was prepared from compound 10 as described above for the other 103 
amide derivatives (Scheme 5b).  HPLC-ESI-MS (chromatogram and analysis in supplementary 104 
information, page S32) and HSQC NMR (supplementary information S18, S20) indicated that 105 
compound 11 is mainly (~80%) a mixture of the A2-2 and A2-3 components in a cca. 5:1 ratio, and 106 
contains a small amount of the more apolar components, A2-4 and A2-5 (about 8%). The A3-1 107 
analogue (same as compound 5, was also detected in the mixture in ~6% quantity) Table 1 108 
summarizes the structures of the new derivatives. 109 
It is expected that minor differences between the lipophilicity of A2 components may cause 110 
slight changes in pharmacokinetic parameters. Factor A2-3 is also reported to be somewhat more 111 
active in vitro than the most abundant A2-2, on the other hand, the in vivo efficacy in mice seems 112 
to be the same, reflecting the essentially similar pharmacokinetics[17]. In our study, not much 113 
importance should be ascribed to this, since we have not done in vivo experiments so far. Besides 114 
that, most of the derivatives of teicoplanin A2 reported were isolated as a mixture of A2 factors 1-115 
5. (see e. g. references 9, 11, 13) Probably, neither the small amounts of the A3-1 component 116 
derivatives in our mixtures (10, 11) influence the observed in vitro activities. In relation to this, it 117 
should be noted, that according to Ph. Eur. 9.0, the teicoplanin mixtures used in clinical settings 118 
are allowed to contain as much as 12% of the more polar A3-1 component. 119 
 120 
Table 1 Structures of the prepared teicoplanin analogues 121 
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Compound no. R1 R2 R3 R4 
1 H H 
 
(-D-GlcNAc) 
OH 
2 H H -D-GlcNAc 
 
3 H H -D-GlcNAc 
 
4 H 
 
(-D-Man) 
-D-GlcNAc OH 
5 H -D-Man -D-GlcNAc 
 
6 H -D-Man -D-GlcNAc 
 
7 H H H OH 
8 H H H 
 
9 H H H 
 
10 
 
(N-acyl--D-GlcN) 
R’ =  
8-methylnonanoyl,  
n-decanoyl1 
-D-Man -D-GlcNAc OH 
11 N-acyl--D-GlcN -D-Man -D-GlcNAc 
 
1only the acyl substituents of the most abundant factors (A2-2 and A2-3) are indicated 122 
 123 
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Antibacterial evaluation 124 
A standard panel of eight Gram-positive bacteria was used as a preliminary test including 125 
a vanA positive E. faecalis strain. (Table 2) All tested compounds were active both against the 126 
teicoplanin susceptible and resistant bacteria. However, the most prominent activity against the 127 
VanA E. faecalis was that of compound 3, which was eight times more active than compound 1. 128 
This derivative showed good activity against both teicoplanin resistant S. epidermidis strains as 129 
well, although compound 2 was superior against these bacteria.  130 
Table 2 In vitro antibacterial activity of new teicoplanin derivatives (MIC values in µg/mL) 131 
 Teico
planin 
1 2 3 4 5 6 7 8 9 10 11 
Bacillus subtilis 
ATCC 6633 
0.5 0.6 0.6 0.15 2.5 2.5 1.25 1.25 2.5 2.5 2.5 5 
Staphylococcus 
aureus MSSA 
ATCC 29213 
0.5 0.6 0.3 0.15 2.5 0.6 0.6 1.25 1.25 2.5 2.5 1.25 
Staphylococcus 
aureus MRSA 
ATCC 33591 
0.5 0.3 0.3 0.3 2.5 2.5 1.25 1.25 1.25 2.5 0.6 2.5 
Staphylococcus 
epidermidis 
biofilm forming 
ATCC 35984 
4 0.3 0.07 0.15 1.25 2.5 1.25 0.6 1.25 0.3 2.5 2.5 
Staphylococcus 
epidermidis 
mecA 
16 0.15 0.035 0.07 1.25 2.5 1.25 0.6 1.25 0.3 2.5 5 
Enterococcus 
faecalis ATCC 
29212 (VSE) 
1 0.6 0.15 0.3 1.25 0.3 0.3 0.6 2.5 1.25 0.3 1.25 
Enterococcus 
faecalis ATCC 
51299 vanB 
0.5 1.25 0.6 0.15 2.5 0.6 0.6 0.6 2.5 2.5 2.5 2.5 
Enterococcus 
faecalis 153761 
vanA 
256 1.25 0.6 0.15 2.5 0.6 1.25 2.5 2.5 2.5 2.5 2.5 
MIC: Minimum Inhibitory Concentration ATCC: American Type Culture Collection, MSSA: Methicillin Sensitive 132 
Staphylococcus aureus, MRSA: Methicillin Resistant Staphylococcus aureus, VSE: Vancomycin Sensitive 133 
Enterococcus, mecA: mecA gene expression in Staphylococcus, vanA +: vanA gene positive, vanB +: vanB gene 134 
positive. 1clinical isolate 135 
 136 
Compound 5 with two carbohydrates (-D-mannose and N-acetyl--D-glucosamine) and a 137 
3-(dimethylamino)-1-propyl side chain also displayed high activity against enterococci, but was  138 
less active in the case of MRSA and the coagulase negative staphylococci. The change of the 139 
dimethyl substituent to diethyl (compound 6) seemed to increase the activity only against 140 
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staphylococci. Although the literature indicates, that the derivatives of teicoplanin aglycon usually 141 
display similar or better activity than the analogous pseudoaglycon derivatives, compounds 7-9 142 
were generally less active than the corresponding pseudoaglycons (1-3). The same was true for 143 
derivatives 10 and 11 with all three formerly present carbohydrates. 144 
Six of the compounds (3, 5, 7, 9, 10, 11) were selected for evaluation against clinical isolates 145 
of VanA type VRE listed in Table 3 (19 E. faecium and 1 E. faecalis). All 20 strains tested were 146 
susceptible to the new derivatives. In most cases, the teicoplanin derivatives showed equal, 147 
sometimes better in vitro activity, than oritavancin. The notable superiority of oritavancin was 148 
observed in five cases (entries 14, 15, 17, 18, 19), however with the exception of one strain (entry 149 
17) the MIC values for compound 3 remained under the current MIC breakpoint for teicoplanin. 150 
Compounds 5, 7, 9, 10 and 11 had less consistent activity. By comparing the number of MIC values 151 
obtained above the breakpoint of teicoplanin and vancomycin, the most promising candidate 152 
besides compound 3 seems to be 11, which is a little unexpected considering the lower activity of 153 
this compound seen in the preliminary tests (Table 2.). The other derivatives are essentially similar 154 
in activity against VRE with compound 5 being slightly more active than the rest. 155 
 156 
Table 3 In vitro antibacterial activity of new teicoplanin derivatives against VanA enterococci.  157 
(MIC values in µg/mL) 158 
# Strain Source TEI VAN ORI 3 5 7 9 10 11 
1 E. faecium 8663 bronchus 256 256 2 0.6 2.5 2.5 2.5 2.5 0.6 
2 E. faecium 22285  urine 256 256 2 0.3 1.25 2.5 2.5 1.25 1.25 
3 E. faecium 656 wound 256 256 2 0.6 1.25 1.25 1.25 1.25 1.25 
4 E. faecium 3452 drain 256 256 1 1.25 2.5 2.5 2.5 2.5 1.25 
5 E. faecium 4753 decubitus 256 256 1 0.6 2.5 2.5 2.5 2.5 2.5 
6 E. faecium 11408 drain 256 256 <0,25 0.3 0.3 0.3 0.3 0.3 0.3 
7 E. faecalis 17980 urine 256 256 2 0.15 0.3 0.15 0.6 0.15 0.15 
8 E. faecium 24581 wound 256 256 0.5 0.6 1.25 2.5 2.5 2.5 0.6 
9 E. faecium 25192 haemoculture 256 256 0.5 0.6 2.5 2.5 2.5 2.5 2.5 
10 E. faecium 29007 urine 256 256 0.25 0.3 5 5 2.5 2.5 0.6 
11 E. faecium 30458 cannula 256 256 0.25 0.3 0.3 0.3 5 5 0.3 
12 E. faecium 31482 urine 256 256 0.25 0.3 0.3 0.6 2.5 5 0.3 
13 E. faecium 32445 cannula 256 256 0.5 0.6 0.6 5 0.6 0.3 0.3 
14 E. faecium 35936 urine 256 256 0.25 0.6 0.6 2.5 0.6 0.3 0.3 
15 E. faecium 38276 urine 256 256 0.25 1.5 2.5 5 5 2.5 2.5 
16 E. faecium 38415 wound 256 256 2 1.25 2.5 5 5 2.5 5 
17 E. faecium 38522 decubitus 256 256 1 2.5 5 5 5 5 5 
18 E. faecium 39063 wound 256 256 0.5 1.25 2.5 2.5 2.5 2.5 2.5 
19 E. faecium 39759 drain 256 256 0.25 1.25 5 5 5 5 5 
20 E. faecium 42491 urine 256 256 0.25 0.3 0.3 0.3 0.3 1.25 0.6 
no. of MIC values above the breakpoint for TEI (2 g/mL) 1 10 14 14 13 7 
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no. of MIC values above the breakpoint for VAN (4 g/mL) 0 3 6 5 4 3 
  TEI: teicoplanin, VAN: vancomycin, ORI: oritavancin 159 
 160 
CONCLUSIONS 161 
 Using systematic structural modifications, we could obtain new derivatives of 1 that proved 162 
to have enhanced in vitro activity against VanA enterococci. The MIC values of the new 163 
derivatives, especially compound 3, are comparable to, or in some cases even lower than that of 164 
oritavancin against the tested VRE strains. 165 
Although, in the aforementioned study of the Lepetit group [15] it was concluded, that the 166 
presence of the N-acetyl--D-glucosamine is detrimental to anti-VRE activity, in all of our highly 167 
active compounds, N-acetyl-glucosamine is present. Moreover, on the most active compound 3, 168 
the only carbohydrate moiety is the N-acetyl-D-glucosamine. 169 
Previous findings have clearly demonstrated the influence of the carbohydrate residues of 170 
teicoplanin derivatives on pharmacokinetics. Especially the presence of the N-acyl-glucosamine on 171 
amino acid four is reported to be beneficial [9, 11-13]. Thus, the in vivo potency is likely to be 172 
altered by the presence vs. absence of sugars on the aglycon, regardless of the in vitro activities 173 
observed. Therefore, the reasonable in vitro activity of the fully glycosylated compound 11 besides 174 
pseudoaglycon 3 against VRE presents a good opportunity to compare the pharmacokinetic 175 
differences in the future and decide which would be the better candidate for further modifications. 176 
 177 
ACKNOWLEDGEMENT 178 
The authors are thankful for the VRE strains kindly provided by the Department of Medical 179 
Microbiology at University of Debrecen. This work was supported by the European Regional 180 
Development Fund under the project GINOP-2.3.2-15-2016-00008 and by the European Social 181 
Fund under the project EFOP-3.6.3-VEKOP-16-2017-00009. 182 
 183 
EXPERIMENTAL 184 
General information 185 
3-(dimethylamino)-1-propylamine and 3-(diethylamino)-1-propylamine were purchased 186 
from Tokyo Chemical Industry Co., Ltd. Triflyl azide was prepared as described elsewhere [5]. 187 
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The vancomycin hydrochloride standard used for the antibacterial evaluations was a gift from 188 
TEVA Pharmaceutical Industries Ltd. (Debrecen, Hungary) and teicoplanin was purchased from 189 
Shaanxi Sciphar Biotechnology Co., Ltd (Xi’an, Shaanxi, China).Oritavancin was purchased from 190 
Xi'an Kerui Biotechnology Co., Ltd. (Xi’an, Shaanxi, China) and checked by MALDI-TOF MS, 191 
1D and 2D NMR experiments. Teicoplanin for synthetic purposes was purchased from Xi'an 192 
Sgonek Biological Technology Co., Ltd. (Weiyang Qu, Xian Shi, Shaanxi Sheng, China). The 193 
antibacterial evaluations were carried out as it was described in our previous publication [7].  194 
TLC was performed on Kieselgel 60 F254 (Merck) with detection either by immersing into 195 
ammonium molybdate-sulfuric acid solution followed by heating or by using Pauly’s reagent for 196 
detection. Flash column chromatography was performed using Silica gel 60 (Merck 0.040-0.063 197 
mm). The 1H NMR (400 MHz) 13C NMR (100 MHz) and 2D NMR spectra were recorded with a 198 
Bruker DRX-400 spectrometer at 298K. Chemical shifts are referenced to Me4Si (0.00 ppm for
 1H) 199 
and to the solvent signals (DMSO-d6: 2.50 ppm for 
1H, 39.51 ppm for 13C). MALDI-TOF MS 200 
analysis of the compounds was carried out in the positive reflectron mode using a BIFLEX III mass 201 
spectrometer (Bruker, Bremen, Germany) equipped with delayed-ion extraction. 2,5-202 
Dihydroxybenzoic acid (DHB) was used as matrix and CF3COONa as cationizing agent in DMF. 203 
For analytical RP-HPLC a Waters 2695 Separations Module (Waters Corp., Milford, USA) 204 
was used. The separations were carried out on a VDSpher PUR 100 C18-M-SE, 5 m, 150 x 4.6 205 
mm column (Batch# VD173001) at an injection volume of 10 l, using a flow rate of 1.0 mL/min 206 
with a Waters 2996 DAD set at 254 nm and a Bruker MicroTOF-Q type Qq-TOF MS instrument 207 
(Bruker Daltonik, Bremen, Germany) as detectors.  The following system was used for the elutions: 208 
Solvent A: Water : MeCN 9 : 1 + 0.0025%v/v TFA , Solvent B: MeCN. Gradient: 20% B from 0 209 
to 20 min, from 20% B to 80% B from 20-40 min, 80% B from 40 to 50 min, from 80% B to 20% 210 
B from 50 to 51 min. Solvent A: Water : MeCN 9 : 1 + 0.0025%v/v TFA, Solvent B: MeCN. The 211 
MicroTOF-Q mass spectrometer was equipped with an electrospray ion source. The mass 212 
spectrometer was operated in positive ion mode with a capillary voltage of 3.5 kV, an endplate 213 
offset of −500 V, nebulizer pressure of 1.8 bar, and N2 as drying gas with a flow rate of 9.0 l/min 214 
at 200 °C. The mass spectra were recorded by means of a digitizer at a sampling rate of 2 GHz. 215 
The mass spectra were calibrated externally using the exact masses of clusters [(NaTFA)n+TFA]
- 216 
from the solution of sodium trifluoroacetate (NaTFA). The spectra were evaluated with the 217 
DataAnalysis 3.4 software from Bruker. Elemental analysis (C, H, N) was performed on an 218 
Elementar Vario MicroCube instrument. 219 
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 220 
Synthesis 221 
Compound 2 222 
Teicoplanin A3-2 derivative 1 [7] (120 mg, 0.075 mmol) was dissolved in dry DMF (1 ml). Then, 223 
19 l (0.15 mmol, 2.0 equiv.) of 3-(dimethylamino)-1-propylamine was added followed by 21 l 224 
(0.15 mmol, 2.0 equiv.) of triethylamine and 47 mg (0.09 mmol, 1.2 equiv.) of PyBOP®. After 225 
stirring the mixture at room temperature for 3 hours, additional 19 l of 3-(dimethylamino)-1-226 
propylamine and 39 mg PyBOP® (1.0 equiv.) were added. The addition of the reagents was 227 
repeated another two times over the course of 6 hours. After TLC indicated sufficient conversion, 228 
75 ml of ethyl acetate was added, and the precipitate was filtered off, then washed with diethyl 229 
ether (75 ml). The residue was dissolved in a mixture of acetonitrile:water =  7:3, silica gel was 230 
added and the mixture was evaporated in vacuo. The product was purified by flash chromatography 231 
using a step gradient starting from acetonitrile to acetonitrile:water = 85:15 (+ 0.1 v/v % AcOH). 232 
The obtained powder was dissolved in MeCN:H2O mixture and the pH was set to ~8 by adding 233 
dilute ammonium hydroxide. The mixture was evaporated to dryness then the product was 234 
dissolved in an acetonitrile:water = 7:3 mixture and purified on a Sephadex LH-20 column in the 235 
same solvent mixture to obtain compound 2 as a white powder. The yield was 45 mg (35%). NMR 236 
data and spectra can be found in the supporting information (Table S1). MALDI-TOF m/z 1715.65 237 
[M + Na]+ (calcd. for C84H78Cl2N12NaO23
+, 1715.46). Analysis Calculated for C84H78Cl2N12O23 C 238 
59.54, H 4.64, N 9.92 Found: C 59.36, H 4.81, N 9.80 239 
 240 
Compound 3 241 
Teicoplanin A3-2 derivative 1 (120 mg, 0.075 mmol) was dissolved in dry DMF (1 ml). Then, 24 242 
l (0.15 mmol, 2.0 equiv.) of 3-(diethylamino)-1-propylamine was added followed by 21 l (0.15 243 
mmol, 2.0 equiv.) of triethylamine and 47 mg (0.09 mmol, 1.2 equiv.) of PyBOP®. After stirring 244 
the mixture at room temperature for 3 hours, additional 24 l of 3-(diethylamino)-1-propylamine 245 
and 39 mg PyBOP® (1.0 equiv.) were added. After 3 hours, 75 ml of ethyl acetate was added, and 246 
the precipitate was filtered off, then washed with diethyl ether (75 ml). The residue was dissolved 247 
in a mixture of acetonitrile:water =  7:3, silica gel was added and the mixture was evaporated in 248 
vacuo. The product was purified by flash chromatography using a step gradient starting from 249 
acetonitrile to acetonitrile:water = 85:15 (+ 0.1 v/v % AcOH). The obtained powder was dissolved 250 
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in MeCN:H2O mixture and the pH was set to ~8 by adding dilute ammonium hydroxide. The 251 
mixture was evaporated to dryness then the product was dissolved in an acetonitrile:water = 7:3 252 
mixture and purified on a Sephadex LH-20 column in the same solvent mixture to obtain compound 253 
3 as a white powder. Yield: 45 mg (35%). NMR data and spectra can be found in the supporting 254 
information (Table S1). MALDI-TOF m/z 1743.75 [M + Na]+ (calcd. for C86H82Cl2N12NaO23
+
,
 255 
1743.49). Analysis Calculated for C86H82Cl2N12O23 C 59.96, H 4.80, N 9.76 Found: C 59.77, H 256 
5.01, N 9.58. 257 
 258 
Compound 4 259 
Teicoplanin complex (1.5 g, 0.798 mmol) was dissolved in 90% aqueous TFA (15 ml) and the 260 
reaction mixture was stirred at room temperature. After 2 hours, diethyl ether was added (150 ml) 261 
and the precipitate was filtered. The solid residue was washed with an additional 100 ml of diethyl 262 
ether and dried. The compound was purified by flash chromatography using a step gradient starting 263 
from acetonitrile:water = 9:1 to acetonitrile:water 75:25 (+ 0,1 v/v% AcOH). The yield of 264 
teicoplanin A3-1 [8] was 990 mg (78%). This material was dissolved in pyridine (40 ml), and Et3N 265 
was added (1.24 mmol, 2 equiv., 174 l) followed by freshly prepared triflyl azide (1.46 mmol, 266 
2.35 equiv.) in dry pyridine (4 ml). Then an aqueous solution of 15 mg of copper(II)-sulfate 267 
pentahydrate (2 ml) was added and the reaction mixture was stirred for 16 h at room temperature. 268 
After the addition of 300 ml ethyl acetate, a solid precipitated, which was filtered off and washed 269 
with 200 ml of ether, yielding 1.0 g of crude azido teicoplanin A3-1. This material was dissolved 270 
in a mixture of acetonitrile:water = 7:3, silica gel was added, then the mixture was evaporated. The 271 
compound was purified by flash chromatography using a step gradient starting from 100% 272 
acetonitrile to acetonitrile:water 88:12 (+ 0,1 v/v% AcOH). The yield was 540 mg. 150 mg (0.094 273 
mmol) of this compound was dissolved in a tert-butanol:water = 1:1 mixture (2 ml). Then, 21 l 274 
(0.118 mmol, 1.25 equiv.) of 1-(prop-2-yn-1-yloxy)naphthalene was added followed by ca. 3 mg 275 
(~15 mol%) of CuSO4 x 5H2O in 200 l of water and 17 mg (0.096 mmol, 1 equiv.) of L-ascorbic 276 
acid. The mixture was stirred overnight at room temperature. After the addition of silica gel, 277 
solvents were evaporated, and the product was purified by flash chromatography using a step 278 
gradient starting from acetonitrile to acetonitrile:water = 87:13 yielding 55 mg (14% for three steps) 279 
of the desired compound. NMR data and spectra can be found in the supporting information (Table 280 
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S1). MALDI-TOF  m/z 1793.60 [M + Na]+ (calcd. for C85H76Cl2N10NaO29
+, 1793.40). Analysis 281 
Calculated for C85H76Cl2N10O29 C 57.60, H 4.32, N 7.90 Found: C 57.35, H 4.58, N 7.72. 282 
 283 
Compound 5 284 
Compound 4 (130 mg, 0.073 mmol) was dissolved in dry DMF (1 ml). Then, 19 l (0.15 mmol, 285 
2.0 equiv.) of 3-(dimethylamino)-1-propylamine was added followed by 21 l (0.15 mmol, 2.0 286 
equiv.) of triethylamine and 47 mg (0.09 mmol, 1.2 equiv.) of PyBOP®. After stirring the mixture 287 
at room temperature for 3 hours, additional 19 l of 3-(dimethylamino)-1-propylamine and 39 mg 288 
PyBOP® (1.0 equiv.) were added. After 3 hours, 75 ml of ethyl acetate was added, and the 289 
precipitate was filtered off, then washed with diethyl ether (75 ml). The residue was dissolved in a 290 
mixture of acetonitrile:water =  7:3, silica gel was added and the mixture was evaporated in vacuo. 291 
The product was purified by flash chromatography using a step gradient starting from acetonitrile 292 
to acetonitrile:water = 78:22 (+ 0,1 v/v % AcOH) yielding 41 mg (30%) of the desired compound. 293 
NMR data and spectra can be found in the supporting information (Table S1). MALDI-TOF m/z 294 
1877.82 [M + Na]+ (calcd. for C90H88Cl2N12NaO28
+, 1877.51). Analysis Calculated for 295 
C90H88Cl2N12O28 C 58.22, H 4.78, N 9.05 Found: C 58.04, H 5.03, N 8.87. 296 
 297 
Compound 6 298 
Compound 4 (88 mg, 0.05 mmol) was dissolved in dry DMF (1 ml). Then, 14 l (0.1 mmol, 2.0 299 
equiv.) of triethylamine was added followed by 78 l (0.5 mmol, 10 equiv.) of 3-(diethylamino)-300 
1-propylamine and 31 mg (0.06 mmol, 1.2 equiv.) of PyBOP®. After stirring the mixture at room 301 
temperature for 1 hour, additional 10 mg (0.4 equiv.) of PyBOP® was added. After another hour, 5 302 
mg (0.2 equiv.) of PyBOP® was added and in 60 minutes the starting material was consumed 303 
(checked by TLC). Ethyl acetate (75 ml) was added, and the precipitate was filtered off and washed 304 
with ether (75 ml). The residue was dissolved in a mixture of acetonitrile:water =  7:3, silica gel 305 
was added and the mixture was evaporated in vacuo. The product was purified by flash 306 
chromatography using a step gradient starting from acetonitrile to acetonitrile:water = 78:22 (+ 0,1 307 
v/v % AcOH) yielding 43 mg (46%) of the desired compound. NMR data and spectra can be found 308 
in the supporting information (Table S1). MALDI-TOF m/z 1883.45 [M + H]+ (calcd. for 309 
C92H93Cl2N12O28
+, 1883.56). Analysis Calculated for C92H92Cl2N12O28 C 58.63, H 4.92, N 8.92 310 
Found: C 58.48, H 5.20, N 8.76 311 
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 312 
Compound 7 313 
4.00 g (2.13 mmol) of teicoplanin complex was heated in 90% aqueous TFA for 6 hours then 314 
worked up as it is published in the literature [8], followed by treatment with TfN3 as described 315 
earlier[5]. After chromatographic purification, 450 mg (0.367 mmol) of azido teicoplanin aglycon 316 
was obtained. This material was dissolved in a tert-butanol:water = 1:1 mixture (6 ml). Then, 83 317 
l (0.46 mmol, 1.25 equiv.) of 1-(prop-2-yn-1-yloxy)naphthalene was added followed by ca. 14 318 
mg (~15 mol%) of CuSO4 x 5H2O in 200 l of water and 65 mg (0.096 mmol, 1.0 equiv.) of L-319 
ascorbic acid in 500 l of water. A few drops of acetonitrile was added to effect homogenity. The 320 
mixture was stirred overnight at room temperature. The reaction mixture was concentrated to a 321 
small volume and ethyl acetate was added. The precipitate was filtered off and washed with ether. 322 
The solid was dissolved in a minimum amount of acetonitrile:water = 7:3 and was loaded on a 323 
column containing Sephadex LH-20 in the same solvent mixture. Fractions were checked by TLC 324 
(cellulose, eluent = nPrOH:cc.NH4OH:H2O = 7:3:2). Fractions containing the desired compound 325 
were pooled and concentrated to a small volume. To this, silica gel was added and the mixture was 326 
evaporated to dryness. Flash chromatography was used for further purification using a step gradient 327 
starting from acetonitrile to acetonitrile:water 93:7, yielding 255 mg (49% from azido teicoplanin 328 
aglycon) of the title compound. NMR data and spectra can be found in the supporting information 329 
(Table S1). MALDI-TOF m/z 1428.09 [M + Na]+ (calcd. for C71H53Cl2N9NaO19
+, 1428.27). 330 
Analysis Calculated for C71H53Cl2N9O19 C 60.60, H 3.80, N 8.96 Found: C 60.32, H 4.04, N 8.79 331 
 332 
Compound 8 333 
Compound 7 (125 mg, 0.09 mmol) was dissolved in DMF (1.5 mL). 2 equiv. of Et3N (0.178 mmol, 334 
24.8 L) was added, then N,N-dimethyl-1,3-propanediamine (3.0 equiv., 0.27 mmol, 34 L) 335 
followed by PyBOP (1.2 equiv., 55 mg). After 2 hours, EtOAc was added, the precipitate filtered 336 
and washed with diethyl ether. The crude product was dissolved in MeCN:H2O 1:1 mixture and 337 
evaporated to dryness after the addition of a small amount of silica gel. The product was purified 338 
by flash column chromatography using step gradient elution (MeCN:H2O = 95:5, 92:8, 9:1, 87:13 339 
+ 0.1% V/V AcOH) yielding the title compound (58 mg, 44%) as a white powder. NMR data and 340 
spectra can be found in the supporting information (Table S1). MALDI-TOF m/z 1512.18 [M + 341 
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Na]+ (calcd. for C76H65Cl2N11NaO18
+, 1512.38). Analysis Calculated for C76H65Cl2N11O18 C 61.21, 342 
H 4.39, N 10.33 Found: C 60.96, H 4.58, N 10.10 343 
 344 
Compound 9 345 
Compound 7 (100 mg, 0.071 mmol) was dissolved in DMF (1.3 mL). 2 equiv. of Et3N (0.142 346 
mmol, 20 L) was added, then N,N-diethyl-1,3-propanediamine (3.0 equiv., 0.213 mmol, 34 L) 347 
followed by PyBOP (1.2 equiv., 44 mg). After 2 hours, EtOAc was added, the precipitate filtered 348 
and washed with diethyl ether. The crude product was dissolved in MeCN:H2O 1:1 mixture and 349 
evaporated to dryness after the addition of a small amount of silica gel. The product was purified 350 
by flash column chromatography using step gradient elution (MeCN:H2O = 95:5, 92:8, 9:1, 88:12 351 
+ 0.1% V/V AcOH) yielding the title compound (39 mg, 36%) as a white powder. NMR data and 352 
spectra can be found in the supporting information (Table S1). MALDI-TOF m/z 1540.18 [M + 353 
Na]+ (calcd. for C78H69Cl2N11NaO18
+, 1540.41). Analysis Calculated for C78H69Cl2N11O18 C 61.66, 354 
H 4.58, N 10.14 Found: C 61.40, H 4.86, N 9.82 355 
 356 
Compound 10 357 
A solution of fresh TfN3 was prepared using the following amounts: 2 mL pyridine (solvent), 134 358 
L Tf2O (0.8 mmol, 2.35 equiv.) and 65 mg NaN3 (1.0 mmol). Teicoplanin complex (640 mg, cca. 359 
0.34 mmol) was suspended in 15 mL pyridine. 2.0 equiv. of Et3N (95 L) was added followed by 360 
the TfN3 reagent, and CuSO4 x 5H2O (10 mg) dissolved in 1.0 mL water. The reaction mixture 361 
became green and homogenous. After stirring overnight at room temperature, EtOAc was added, 362 
the precipitate was filtered and washed with diethyl ether, acetonitrile, then ether again. The crude 363 
product was dissolved in MeOH, some silica gel was added and the mixture was evaporated to 364 
dryness. The product was purified by flash chromatography, using a step gradient elution starting 365 
from 100% MeCN, followed by MeCN : H2O = 9:1, 85:15, 8:2, then 75:25 yielding azido 366 
teicoplanin A2 (400 mg, 0.21 mmol) which was dissolved in a mixture of t-BuOH:H2O =1:1 (3 367 
mL). -naphthyl propargyl ether (48 mg, 1.25 equiv.) was added. Then, a 100 l aqueous solution 368 
of CuSO4 x 5 H2O (7 mg, ca. 15 mol%) was added followed by 1.0 equiv. of L-ascorbic acid (37 369 
mg) in 100 l of water. The solution was stirred at room temp. for about 16 hours, after which 370 
silica gel was added, and the mixture was evaporated to dryness. The product was purified by flash 371 
column chromatography using a step gradient starting with 100% MeCN to MeCN:H2O 88:12 372 
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(+0.1 v/v % AcOH). After evaporating the solvents, the product was dissolved in DMSO (1.5 mL) 373 
and was filtered through a small piece of cotton. To the obtained clear solution EtOAc was added. 374 
The precipitated product was filtered off and washed with diethyl ether several times. The yield 375 
was 210 mg (48%). NMR data, spectra and HPLC chromatogram can be found in the supporting 376 
information. MS (HPLC-ESI-MS) m/z 2088.616 [M + H]+ (component A2-2) (2088.629 calcd. for 377 
C101H106Cl2N11
+). See supplementary information for further analysis. 378 
 379 
Compound 11 380 
Compound 10 (80 mg, 0.038 mmol) was dissolved in a mixture of DMF:DMSO =1:1 (1 ml) and 2 381 
equiv. of Et3N was added (0.076 mmol, 10.6  l) followed by 2.5 equiv. of N,N-dimethyl-1,3-382 
propanediamine0.095 mmol, l). then 1.0 equiv. of PyBOP was added (0.038 mmol, 20 mg) 383 
and the solution was stirred for 3 hours, after which the starting material was consumed (as 384 
indicated by TLC). Diethyl ether was added, and the resulting precipitate was filtered off and 385 
washed several times with ether. The crude product was dissolved in a small of amount of 386 
MeCN:H2O 1:1 mixture, n-butanol was added followed by silica gel. The mixture was evaporated 387 
to dryness. Flash chromatography was used for purification (step gradient from MeCN:H2O 95:5 388 
(+0.1 v/v% AcOH) to MeCN:H2O 8:2 (+0.1 v/v% AcOH). The obtained powder was dissolved in 389 
MeCN:H2O mixture and the pH was set to ~8 by adding dilute ammonium hydroxide. The mixture 390 
was evaporated to dryness then the product was dissolved in an acetonitrile:water = 7:3 mixture 391 
and purified on a Sephadex LH-20 column in the same solvent mixture, yielding compound 11 (26 392 
mg, 32 %) as a white powder. NMR data, spectra and HPLC-ESI-MS analysis can be found in the 393 
supporting information. MS (HPLC-ESI-MS) m/z 2172.738 [M + Na]+ (component A2-2) 394 
(2172.735 calcd. for C106H118Cl2N13O33
+). See supplementary information for further analysis. 395 
 396 
eSupplementary information is available at The Journal of Antibiotics website. 397 
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